Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Asis K. Sarkar"'
Publikováno v:
Data in Brief, Vol 29, Iss , Pp - (2020)
Separase Inhibitor–Sepin-1 has shown great promise as a developmental chemotherapeutic agent to treat Separase-overexpressing tumors, however, very little is known about its toxicity profile. Here we present the data set of organ weights, hematolog
Externí odkaz:
https://doaj.org/article/c0af3a99d03140a3bc5d4f5c8f3d1eea
Autor:
Eric T Williams, Roger J. Waltzman, Jack P. Higgins, Asis K. Sarkar, Aimee Iberg, Erin Willert
Publikováno v:
Cancer Research. 80:P1-18
Engineered toxin bodies (ETBs) are differentiated, targeted therapeutics comprised of a proprietarily engineered form of Shiga-like Toxin A subunit (SLTA) genetically fused to antibody-like binding domains. ETBs work through novel mechanisms of actio
Autor:
Scott R. Gilbertson, Silviya Demerzhan, Feng Li, Nenggang Zhang, Debananda Pati, Asis K. Sarkar
Publikováno v:
Biochemical pharmacology. 174
Separase, a sister chromatid cohesion-resolving enzyme, is an oncogene and overexpressed in many human cancers. Sepin-1 (2,2-dimethyl-5-nitro-2H-benzimidazole-1,3-dioxide) is a potent separase inhibitor that impedes cancer cell growth, cell migration
Autor:
Sara LeMar, Hilario J. Ramos, Garrett L. Robinson, Joseph D. Dekker, Aimee Iberg, Asis K. Sarkar, Banmeet Anand, Brigitte Brieschke, Melissa M. Singh, Jack P. Higgins, Jay Zhao, Erin Willert
Publikováno v:
Cancer Research. 80:3366-3366
Engineered toxin bodies (ETBs) comprised of a proprietarily engineered Shiga-like Toxin A subunit (SLTA) genetically fused to antibody-like binding domains work through novel mechanisms of action and can force internalization, self-route through intr
Publikováno v:
Data in Brief, Vol 29, Iss, Pp-(2020)
Data in Brief
Data in Brief
Separase Inhibitor–Sepin-1 has shown great promise as a developmental chemotherapeutic agent to treat Separase-overexpressing tumors, however, very little is known about its toxicity profile. Here we present the data set of organ weights, hematolog
Autor:
Roger J. Waltzman, Sara LeMar, Hilario J. Ramos, Garrett L. Robinson, Joseph D. Dekker, Brigitte Brieschke, Garrett L. Cornelison, Aimee T. Iberg, Asis K. Sarkar, Erin Willert, Jay Zhao
Publikováno v:
Journal of Clinical Oncology. 38:12-12
12 Background: Engineered toxin bodies (ETBs) comprised of a proprietarily engineered Shiga-like Toxin A subunit (SLT-A) genetically fused to antibody-like binding domains work through novel mechanisms of action and can force internalization, self-ro
Autor:
Jack T. Higgins, Roger J. Waltzman, Aimee T. Iberg, Asis K. Sarkar, Eric T Williams, Erin Willert
Publikováno v:
Journal of Clinical Oncology. 38:433-433
433 Background: Engineered toxin bodies (ETBs) are comprised of a proprietarily engineered Shiga-like Toxin A subunit genetically fused to antibody-like binding domains. MT-5111 is a de-immunized ETB targeting HER2 for solid tumors. MT-5111 works thr
Publikováno v:
Pathology - Research and Practice. 216:152730
Sepin-1 is a small compound that inhibits enzymatic activity of Separase and growth of cancer cells. As part of the IND-enabling studies to develop Sepin-1 as a chemotherapeutic agent, herein we have profiled the toxicity of Sepin-1 in Sprague-Dawley
Autor:
Garrett L. Robinson, Jack P. Higgins, Brigitte Brieschke, Michaela Sousares, Hilario J. Ramos, Jensing Liu, Sara Le Mar, Veronica Partridge, Erin Willert, Joseph D. Dekker, Shaoyou Chu, Pablo A. Maceda, Aimee Iberg, Asis K. Sarkar
Publikováno v:
Cancer Research. 79:3900-3900
Engineered Toxin Bodies (ETBs) are comprised of a deimmunized Shiga-like toxin subunit A (SLTA) genetically fused to an antibody-like targeting domain. The antibody targeting domain allows for specific targeting of cancer cells while the SLTA compone
Autor:
William C. Satterfield, Asis K. Sarkar, Stepanie Buchl, Morito Sakaue, Michele Follen, Katsuyuki Hamada, Jack A. Roth, Michale E. Keeling, Jagannandha Sastry
Publikováno v:
Gynecologic Oncology. 99:S177-S186
Background. One major concern about adenoviral vectors for repetitive gene delivery is the induction of an immune response to the vector, thus impeding effective gene transduction. Methods. To assess the immune response to the adenoviral vector, repe